Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/33393
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-08-08T07:29:18Z | - |
dc.date.available | 2023-08-08T07:29:18Z | - |
dc.date.issued | 2016-09-09 | - |
dc.identifier.citation | Kalyoncu, U. vd. (2017). ''The psoriatic arthritis registry of Turkey: Results of a multicentre registry on 1081 patients''. Rheumatology, 56(2), 279-284. | en_US |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.issn | 1462-0332 | - |
dc.identifier.uri | https://doi.org/10.1093/rheumatology/kew375 | - |
dc.identifier.uri | https://academic.oup.com/rheumatology/article/56/2/279/2447889 | - |
dc.identifier.uri | http://hdl.handle.net/11452/33393 | - |
dc.description | Çalışmada 48 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | tr_TR |
dc.description.abstract | Objective. The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. Methods. The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. Results. One thousand and eighty-one patients (64.7% women) with a mean (S.D.) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (S.D.) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. Conclusion. The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Psoriatic arthritis | en_US |
dc.subject | Registry | en_US |
dc.subject | Disease activity | en_US |
dc.subject | Inflammatory back-pain | en_US |
dc.subject | Ankylosing-spondylitis | en_US |
dc.subject | Clinical history | en_US |
dc.subject | Disease-activity | en_US |
dc.subject | Health-care | en_US |
dc.subject | Classificationcriteria | en_US |
dc.subject | Criteria | en_US |
dc.subject | Spondyloarthritis | en_US |
dc.subject | Recommendations | en_US |
dc.subject | Prevalence | en_US |
dc.subject.mesh | Activities of daily living | en_US |
dc.subject.mesh | Age distribution | en_US |
dc.subject.mesh | Antirheumatic agents | en_US |
dc.subject.mesh | Arthritis, psoriatic | en_US |
dc.subject.mesh | Fatigue | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Health services needs and demand | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Patient reported outcome measures | en_US |
dc.subject.mesh | Registries | en_US |
dc.subject.mesh | Remission induction | en_US |
dc.subject.mesh | Severity of Illness Index | en_US |
dc.subject.mesh | Sex distribution | en_US |
dc.subject.mesh | Tumor necrosis factor-alpha | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.mesh | Adult | en_US |
dc.title | The psoriatic arthritis registry of Turkey: Results of a multicentre registry on 1081 patients | en_US |
dc.type | Book | en_US |
dc.identifier.wos | 000397050600018 | tr_TR |
dc.identifier.scopus | 2-s2.0-85039809580 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 279 | tr_TR |
dc.identifier.endpage | 286 | tr_TR |
dc.identifier.volume | 56 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Rheumatology | en_US |
dc.contributor.buuauthor | Öksüz, Mustafa Ferhat | - |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 27794533 | tr_TR |
dc.subject.wos | Rheumatology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 56016440100 | tr_TR |
dc.subject.scopus | Complex; Viscometry; Schiff Bases | en_US |
dc.subject.emtree | Adalimumab | en_US |
dc.subject.emtree | Disease modifying antirheumatic drug | en_US |
dc.subject.emtree | Etanercept | en_US |
dc.subject.emtree | Glucocorticoid | en_US |
dc.subject.emtree | Golimumab | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Tumor necrosis factor inhibitor | en_US |
dc.subject.emtree | Antirheumatic agent | en_US |
dc.subject.emtree | Tumor necrosis factor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Arthralgia | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Axial disease | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | DAS28 | en_US |
dc.subject.emtree | Disease activity | en_US |
dc.subject.emtree | Disease control | en_US |
dc.subject.emtree | Disease duration | en_US |
dc.subject.emtree | Fatigue | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Health assessment questionnaire | en_US |
dc.subject.emtree | Health care need | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Joint swelling | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Monotherapy | en_US |
dc.subject.emtree | Oligoarticular psoriatic arthritis | en_US |
dc.subject.emtree | Patient-reported outcome | en_US |
dc.subject.emtree | Physician | en_US |
dc.subject.emtree | Polyarticular psoriatic arthritis | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Psoriatic arthritis | en_US |
dc.subject.emtree | Register | en_US |
dc.subject.emtree | Remission | en_US |
dc.subject.emtree | Sex difference | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.emtree | Visual analog scale | en_US |
dc.subject.emtree | Age distribution | en_US |
dc.subject.emtree | Antagonists and inhibitors | en_US |
dc.subject.emtree | Arthritis | en_US |
dc.subject.emtree | Psoriatic | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Complication | en_US |
dc.subject.emtree | Daily life activity | en_US |
dc.subject.emtree | Fatigue | en_US |
dc.subject.emtree | Health service | en_US |
dc.subject.emtree | Multicenter study | en_US |
dc.subject.emtree | Pathophysiology | en_US |
dc.subject.emtree | Severity of illness index | en_US |
dc.subject.emtree | Sex ratio | en_US |
dc.subject.emtree | Turkey | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Öksüz_vd_2017.pdf | 173.41 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License